Cadonilimab by Akeso for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC).
Cadonilimab is under clinical development by Akeso and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC).
What's Your Reaction?
